LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Fisher & Paykel Healthcare Corporation Limited Provides Earnings Guidance for the Year 2025 CI
Fisher & Paykel Healthcare Corporation Limited Announces Final Dividend for the Full Year 2024, Payable on 10 July 2024 CI
Fisher & Paykel Healthcare Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
New Zealand Shares Flat; Fisher & Paykel Healthcare's Fiscal 2024 Net Profit Falls MT
Fisher & Paykel Healthcare's Net Profit Nearly Halves in Fiscal Year 2024; Shares Rise 6% MT
Transcript : Fisher & Paykel Healthcare Corporation Limited, 2024 Earnings Call, May 29, 2024
New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask MT
Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea MT
JPMorgan Upgrades Fisher & Paykel Healthcare to Neutral from Underweight; Price Target is NZ$24.00 MT
New Zealand Shares Jump on Rate Cut Hopes; WasteCo Raises NZ$3 Million from Convertible Bond Offer MT
Fisher & Paykel Issues Limited Recall of Airvo Devices; Flags NZ$12 Million Hit MT
Fisher & Paykel Healthcare Corporation Limited Initiates Voluntary Limited Recall of Airvo 2 and myAirvo 2 Devices Manufactured Before 14 August 2017 CI
Fisher & Paykel Healthcare Expects NZ$1.73 FY Billion Operating Revenue MT
Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024 CI
New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare's Chair to Retire MT
Fisher & Paykel Healthcare Corporation Limited Announces Board Changes CI
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to NZ$24.12 From NZ$23.12, Keeps at Equalweight MT
Morgan Stanley Adjusts Fisher & Paykel Healthcare’s Price Target to AU$22.19 From AU$21.50, Keeps at Equalweight MT
Australian shares gain as financials shine; market focus on inflation data RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed RE
New Zealand Shares Rise on Strong Trading in Services Sector MT
Fisher & Paykel Healthcare Appoints COO MT
Fisher & Paykel Healthcare Corporation Limited Announces Board Changes CI
ResMed, Inc. continues to make headway in the sleep market Our Logo
Chart Fisher & Paykel Healthcare Corporation Limited
More charts
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The Company provides medical device products and systems for use in both hospital and homecare settings. Its hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include its continuous positive airway pressure (CPAP) therapy masks as well as flow generators, interfaces, and data management technologies. The Company’s products are sold in over 120 countries worldwide. It operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, and others.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
30.77 NZD
Average target price
25.95 NZD
Spread / Average Target
-15.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW